Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia - Wikidata - wikimedia - TriplyDB

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

http://www.wikidata.org/entity/Q34151093

about

Antibiotics for community-acquired pneumonia in adult outpatients Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin Review of nemonoxacin with special focus on clinical development Investigational antimicrobial agents of 2013.Newer antibacterials in therapy and clinical trials Determination of a novel nonfluorinated quinolone, nemonoxacin, in human feces and its glucuronide conjugate in human urine and feces by high-performance liquid chromatography-triple quadrupole mass spectrometry.Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers New antibiotic agents in the pipeline and how they can help overcome microbial resistance.Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model.The potential role of nemonoxacin for treatment of common infections.In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.Assessment of bias in outcomes reported in trials on pneumonia: a systematic review.Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Nemonoxacin: first global approval.Participation of elderly adults in randomized controlled trials addressing antibiotic treatment of pneumonia.Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia.Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.Effects of an Al(3+)- and Mg(2+)-containing antacid, ferrous sulfate, and calcium carbonate on the absorption of nemonoxacin (TG-873870) in healthy Chinese volunteers.Antibiotic resistance: challenges and successes in respiratory infection.Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.Are fluoroquinolones superior antibiotics for the treatment of community-acquired pneumonia?Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones.

P2860

Q24193127-F490BF5B-55AC-4C2E-A1A1-079D0AF3D2A1 Q26746616-F4E2FA30-AD50-482A-969B-D0691F28C636 Q26830778-855E43B3-D93B-4D8A-BCE6-A2BD56978FDC Q34375204-4FDFA649-39B4-4D7B-AF64-8FDF1BA675D5 Q34488329-DE5F2333-3CA3-40B5-A1A4-41F16A9752BA Q35342029-850EE331-6F1E-4348-A725-52BCBF36536C Q36498735-F492FE20-D13B-4629-BCAC-A3967707F6EF Q36845895-DBCE7996-4D68-44C8-A942-A0D1ED2FCEFF Q36969966-B99BAB6F-3993-4B9E-B48C-92A2C50A9FA9 Q37842543-DB03A961-4321-491D-B225-13027792AE4A Q37845251-B6059BE5-4726-4B6B-A9E3-B2F293DC9C40 Q38172440-3D9B4C40-0B19-43C9-9BC6-5DE46FFD1CC6 Q38233471-97829DE2-E20F-4F3F-BC0A-40D8DA61BF8A Q38235601-099986AC-2216-4461-AD68-1B0DF3747DBE Q38358209-198107B2-B55C-4BED-91E3-EF03716D0434 Q38648594-C9338E1C-0E47-40AC-878C-73C8F6BEFBF0 Q39118434-31EB0D38-FFA5-4FA2-9148-58A2FC00CA63 Q39362169-FF530305-5E58-417B-B6AB-F2CC0F7DC59D Q39706231-36BAB030-472C-409A-B88A-11F429CA6699 Q42005626-5CFFB41A-CBF8-410C-8EAF-66CF927A2BD9 Q44268356-0C0BBA54-F0EE-4118-AC9F-A5F5640E95A5 Q46887329-7089E648-4D68-4C38-A53A-AFD94A9FF3BB Q48023992-3516BE9C-8771-4BAE-9880-7AA1CFE26B1B Q51703562-2FDFCF54-00AE-4435-B2E6-5DA7665A7C93

P2860

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

http://www.wikidata.org/entity/Q34151093

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

@ast

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

@en

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

@nl

type

label

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

@ast

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

@en

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

@nl

prefLabel

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

@ast

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

@en

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

@nl

P1433

Q34151093-96C71B9B-A4E3-4B6B-8482-838EEA60E8FD

P1476

Q34151093-8F913556-7770-4927-90C2-08EFFCB9D980

P2093

Q34151093-017435D2-80D9-4B63-A20B-6C74459449B5

Q34151093-20091A4F-784B-4DF8-A3BC-EB5B9CA45A0E

Q34151093-4C7FD78D-C57D-4AA1-A4DD-334412FB64E0

Q34151093-5C836968-31F1-457E-BD0A-C3923F28E268

Q34151093-7FA8CB59-1A18-4948-B44C-DB519DBED448

Q34151093-8D7F2878-2E17-4EFF-B1D2-9CCC4FA9D3AC

Q34151093-9064103F-DAF8-40AE-9DAE-0E38DE57177B

Q34151093-9E506FD2-8F1C-47EF-A26E-B818F632FB6D

Q34151093-A265879B-2418-4D04-A49F-FC74DF7E7C8B

Q34151093-CFFF4DE4-87C6-4620-981E-E95E5A9FF081

P2860

Q34151093-09A72F83-E0EF-42C8-9026-5BCCFDE3B8E9

Q34151093-0B8698F6-517F-4B2D-92CF-3C3BA4567D5A

Q34151093-0E01B825-1DFF-4389-B825-B0CD923AB772

Q34151093-11E11D3D-93B4-4AF9-B832-F9E3C813EE81

Q34151093-2CD128AF-2DF2-4B72-A3A8-621ECDD626B1

Q34151093-38AB7392-A4B0-4F61-A223-750F9CDD4FA1

Q34151093-410327CF-9759-46EB-A633-1AF4BFC5F336

Q34151093-47912F19-EBAC-4858-920C-9D73ACDCEF18

Q34151093-483DA364-012E-47D0-93E6-351BC96F85DA

Q34151093-528DB63F-2337-4613-BD28-663AFB88E4FA

P304

Q34151093-9EDE4475-B617-4184-AE86-7382FEBA9425

P31

Q34151093-0A9B5B7E-662E-4863-9BFD-71D4FB905CFC

P356

Q34151093-500EBA41-2235-4343-B098-76636E0DB22F

P407

Q34151093-8B0C3F04-7B00-4442-97F9-F5A19C7C4F63

P433

Q34151093-FAE8014D-DEEB-4E54-B09D-B50DCD43B124

P478

Q34151093-DD1B0B53-B1E4-4AC2-9A4A-4DE570C604B3

P577

Q34151093-DF3141BE-2922-4804-8193-40D522948019

P698

Q34151093-9EB5F90D-1771-422B-82BA-8E20B15E2224

P921

Q34151093-F38829DF-984F-4E62-8D56-696190EE3C04

P932

Q34151093-FE41FB75-53A1-45D6-9789-5123B4A69306

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

@en

P2093

Andrè J Bester

http://www.w3.org/2001/XMLSchema#string

Chi-Hsin R King

http://www.w3.org/2001/XMLSchema#string

David T Chung

http://www.w3.org/2001/XMLSchema#string

Dirkie J J van Rensburg

http://www.w3.org/2001/XMLSchema#string

Ismail H Mitha

http://www.w3.org/2001/XMLSchema#string

Joseph Kasumba

http://www.w3.org/2001/XMLSchema#string

Li-Wen Chang

http://www.w3.org/2001/XMLSchema#string

Ming-Chu Hsu

http://www.w3.org/2001/XMLSchema#string

Ming-Lin Ho

http://www.w3.org/2001/XMLSchema#string

Ren-Guang Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

BTS Guidelines for the Management of Community Acquired Pneumonia in Adults

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.

Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.

Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.

Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.

Community-acquired pneumonia. A prospective outpatient study.

The burden of community-acquired pneumonia in seniors: results of a population-based study.

Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.

P304

4098-4106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00295-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20660689

http://www.w3.org/2001/XMLSchema#string

P921

P932

2944601

http://www.w3.org/2001/XMLSchema#string